// App-Quantinova.ai

e16151 : The comparative efficacy of atezolizumab and bevacizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).

Researchers

Presenter

  • David Trueman

Principal Investigators

  • Yifeng Liu

  • Melanie Lucero

  • Genevieve Meier

Medical Centers

  • Medtronic, Health Economics, London, United Kingdom

  • (Former) Eisai, Inc., Woodcliff Lake, NJ

  • Eisai Inc, Woodcliff Lake, NJ

Locations

  • United Kingdom

  • United States

Companies

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved